[Retracted] Antiviral Therapy with Entecavir following Antituberculosis Therapy Alleviates Liver Injury and Restores Innate Immunity in Tuberculosis Patients Coinfected with Hepatitis B Virus

Table 2

The concentration of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ T cells between the two groups before treatment and 6 months after treatment.

Group	Time	CD4^+ (%)	CD8^+ (%)	CD4^+/CD8^+	CD3^+ (%)
Anti-TB group (n = 50)	Before treatment	34.84 ± 5.47	34.38 ± 4.11	1.17 ± 0.21	42.41 ± 6.48
	6 months after treatment	37.19 ± 5.98	28.19 ± 3.01	1.43 ± 0.39	48.63 ± 7.85
Antiviral group (n = 50)	Before treatment	34.02 ± 5.15	34.37 ± 4.16	1.19 ± 0.23	42.63 ± 6.54
	6 months after treatment	41.14 ± 6.84	23.34 ± 4.15	1.79 ± 0.43	54.85 ± 8.26
t/P (within the anti-TB group)		5.397/0.001	8.372/0.001	3.192/0.018	4.187/0.014
t/P (within the antiviral group)		6.571/0.001	12.197/0.001	4.146/0.012	5.874/0.003
t/P (between groups)		4.179/0.001	5.175/0.001	2.825/0.024	3.918/0.017